On May 22, Mentor (NYSE:MNT) released fiscal Q4 2006 earnings for the period ended March 31.
- While total revenue, including discontinued operations, beat expectations, earnings per share missed badly, partly due to divestiture expenses of $0.05 per share and equity compensation of $0.01 per share.
- No announcement was made on the timing of final FDA approval for Mentor's new silicone breast implant.
- Forward earnings guidance was not given, even after several promptings by analysts participating in the earnings conference call.
(Figures in thousands, except per-share data)
Income Statement Highlights|
Avg. Est. |
Q4 2006 |
Q4 2005 |
Change | |
|---|---|---|---|---|
|
Sales* |
$131,900 |
$72,402 |
$68,679 |
5.4% |
|
Net Profit** |
-- |
$15,020 |
$8,364 |
79.6% |
|
EPS |
$0.40 |
$0.31 |
$0.19 |
63.2% |
|
Diluted Shares |
51,061 |
48,138 |
6.1% |
** GAAP net profit. Not including discontinued, Q4 2006 = $13,576 or $0.28 EPS and Q4 2005 = $6,158 or $0.14 EPS.
Get back to basics with a look at the income statement.
Margin Checkup|
Q4 2006 |
Q4 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
72.43% |
76.08% |
(3.65) |
|
Operating Margin |
26.27% |
14.77% |
11.50 |
|
Net Margin ** |
20.75% |
12.18% |
8.57 |
** Including discontinued operations.
Margins are the earnings engine. See how they work.
Balance Sheet Highlights|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$200,954 |
$112,894 |
78% |
|
Accounts Rec. |
$58,199 |
$57,218 |
1.7% |
|
Inventory |
$35,219 |
$35,041 |
0.5% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Long Term Debt* |
$164,000 |
$150,970 |
8.6% |
Learn the ways of the balance sheet.
Cash Flow Highlights
No cash flow data provided. Boo!
Find out why Fools always follow the money.
Related Companies:
- Medicis Pharmaceutical (NYSE:MRX)
- Inamed, a subsidiary of Allergan (NASDAQ:AGN)
- Johnson & Johnson (NYSE:JNJ)
Related Foolishness:
- Mentor's earnings prediction.
- Last quarter's holding pattern.
- Mentor may be just right for Anna Nicole.
Johnson & Johnson is a Motley Fool Income Investor selection. Want toget paid to invest? Mathew Emmert and the Income Investor team can show you how. Sign up today for a free30-day guest pass.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
At the time of publication, Jim Mueller had positions in Johnson & Johnson. Fool rules are here.
